Nadclinic Ltd

	Page
Accountants' Report	1
Balance Sheet	2—3
Notes to the Financial Statements	4—7

Report to the director on the preparation of the unaudited statutory accounts of Nadclinic Ltd for the year ended 31 July 2025

To assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Nadclinic Ltd which comprise the Profit and Loss Account, the Balance Sheet and the related notes, from the company’s accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at https://www.accaglobal.com/gb/en/member/standards/rules-and-standards/rulebook.html.

This report is made to the director of Nadclinic Ltd , as a body, in accordance with the terms of our engagement letter dated 05/06/2025. Our work has been undertaken solely to prepare for your approval the accounts of Nadclinic Ltd and state those matters that we have agreed to state to the director of Nadclinic Ltd , as a body, in this report in accordance with the Association of Chartered Certified Accountants as detailed at https://www.accaglobal.com/gb/en/technical-activities/technical-resources-search/2009/october/factsheet-163-audit-exempt-companies.html. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Nadclinic Ltd and its director as a body for our work or for this report.

It is your duty to ensure that Nadclinic Ltd has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit or loss of Nadclinic Ltd . You consider that Nadclinic Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Nadclinic Ltd . For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the financial statements.

31st July 2026

Ascendis Accountants, Business & Tax Advisors Ltd

Chartered Certified Accountants, Taxation and Business Advisors

First Floor, East Wing, Sandfield House

Kings Close, Water Lane

Wilmslow

Cheshire

SK9 5AR

Page 1

Page 2

Nadclinic Ltd

Balance Sheet

As At 31 July 2025

Balance Sheet

Registered number: 11468735

		2025		2024
	Notes	£	£	£	£
FIXED ASSETS
Intangible Assets	4		211,302		231,873
Tangible Assets	5		10,125		25,854

			221,427		257,727
CURRENT ASSETS
Stocks	6	86,488		14,703
Debtors	7	736,219		557,331
Cash at bank and in hand		168,403		67,954

		991,110		639,988
Creditors: Amounts Falling Due Within One Year	8	(603,489 )		(355,180 )

NET CURRENT ASSETS (LIABILITIES)			387,621		284,808

TOTAL ASSETS LESS CURRENT LIABILITIES			609,048		542,535

Creditors: Amounts Falling Due After More Than One Year	9		(819,857 )		(457,172 )

NET (LIABILITIES)/ASSETS			(210,809 )		85,363

CAPITAL AND RESERVES
Called up share capital	10		250,100		250,100
Profit and Loss Account			(460,909 )		(164,737 )

SHAREHOLDERS' FUNDS			(210,809)		85,363

Page 2

Page 3

Nadclinic Ltd

Balance Sheet (continued)

As At 31 July 2025

For the year ending 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Ms Yuqi Feng

Director

31st July 2026

The notes on pages 4 to 7 form part of these financial statements.

Page 3

Page 4

Nadclinic Ltd

Notes to the Financial Statements

For The Year Ended 31 July 2025

Notes to the Financial Statements

1. General Information

Nadclinic Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 11468735 . The registered office is Floor 1, 27 Wimpole Street, London, W1G 8GN.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Going Concern Disclosure

The accounts have been prepared on a going concern basis. This assumption may not be valid since at the balance sheet date the company has net liabilities of £210,809. The validity of the going concern assumption therefore depends on the continued support of the directors, suppliers and the companies bankers and other providers of finance.

2.3. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Sale of goods

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.

Rendering of services

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.4. Intangible Fixed Assets and Amortisation - Other Intangible

Other intangible assets are software. It is amortised on 25% straight line basis.

2.5. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Leasehold	20% straight line
Plant & Machinery	25% straight line
Fixtures & Fittings	25% straight line
Computer Equipment	25% straight line

2.6. Stocks and Work in Progress

Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.

2.7. Foreign Currencies

Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.

Page 4

Page 5

Nadclinic Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 July 2025

2.8. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 14 (2024: 11)

4. Intangible Assets

	Other	Development Costs	Total
	£	£	£
Cost
As at 1 August 2024	55,364	242,159	297,523
Additions	-	15,782	15,782

As at 31 July 2025	55,364	257,941	313,305

Amortisation
As at 1 August 2024	24,280	41,370	65,650
Provided during the period	11,425	24,928	36,353

As at 31 July 2025	35,705	66,298	102,003

Net Book Value
As at 31 July 2025	19,659	191,643	211,302

As at 1 August 2024	31,084	200,789	231,873

Page 5

Page 6

Nadclinic Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 July 2025

5. Tangible Assets

	Land & Property
	Leasehold	Plant & Machinery	Fixtures & Fittings	Computer Equipment	Total
	£	£	£	£	£
Cost
As at 1 August 2024	53,505	38,827	32,145	6,346	130,823
Additions	-	278	-	720	998

As at 31 July 2025	53,505	39,105	32,145	7,066	131,821

Depreciation
As at 1 August 2024	43,251	26,796	31,233	3,689	104,969
Provided during the period	6,074	8,320	778	1,555	16,727

As at 31 July 2025	49,325	35,116	32,011	5,244	121,696

Net Book Value
As at 31 July 2025	4,180	3,989	134	1,822	10,125

As at 1 August 2024	10,254	12,031	912	2,657	25,854

6. Stocks

	2025	2024
	£	£
Stock	86,488	14,703

7. Debtors

	2025	2024
	£	£
Due within one year
Trade debtors	242,295	185,152
Other debtors	493,924	372,179

	736,219	557,331

8. Creditors: Amounts Falling Due Within One Year

	2025	2024
	£	£
Trade creditors	446,056	188,157
Bank loans and overdrafts	6,314	10,032
Other creditors	119,705	101,789
Taxation and social security	31,414	55,202

	603,489	355,180

Page 6

Page 7

Nadclinic Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 July 2025

9. Creditors: Amounts Falling Due After More Than One Year

	2025	2024
	£	£
Bank loans	19,247	25,415
Amounts owed to group undertakings	715,217	-
Other creditors	85,393	431,757

	819,857	457,172

10. Share Capital

	2025	2024
Allotted, called up and fully paid	£	£
2,501,000 Ordinary Shares of £ 0.10 each	250,100	250,100

Page 7